100% renewable electricity by 2025 via RE100 and PPAs Novartis is committed to using 100% renewable electricity across operations by 2025 following RE100 principles. In 2024, 96% of purchased electricity was renewable (up from 92% in 2023). Uses 100% renewable electricity in North America and Europe through virtual power purchase agreements (VPPAs). Participates in Energize, an industry initiative led with Schneider Electric to facilitate market access for renewable electricity procurement among suppliers.
▾ expand
Expanded Scope 3 disclosure categories Novartis discloses Scope 3 emissions categories considered relevant in 2024 including newly disclosed categories. 2023 and 2022 data has been updated accordingly.
▾ expand
TNFD-aligned nature assessment Conducted nature assessment for own operations and upstream supply chain aligned with TNFD LEAP approach. Plan to implement sustainable sourcing program starting with pilot in 2025.
▾ expand
Primary: Site energy efficiency + electrification of fleet (EV100) Reducing energy demand through efficiency initiatives and process innovations, implementing green technologies across operating sites. Transitioning fleet to electric vehicles by 2030 in line with EV100 commitment. Deployed USD 40 million capital expenditure on environmental projects in 2024. Scope 1+2 emissions reduced 20% YoY and 71% from 2016 baseline.
▾ expand
Dependent: Upstream/downstream logistics decarbonisation Transportation Scope 3 emissions managed across upstream (cat 4: 166 ktCO2e) and downstream (cat 9: 111 ktCO2e). Cold-chain and radioligand therapy delivery require quick transport given short isotope half-lives. Investing in regional RLT manufacturing facilities (Indianapolis, Carlsbad CA, Italy, Slovenia) to shorten supply chains.
▾ expand
New 2030 waste reduction target Reduce amount of waste sent for disposal by 30% by 2030 from a 2022 baseline. 2025 target (50% reduction from 2016) already achieved.
▾ expand
Restated 2022/2023 water data 2023 and 2022 water usage performance indicators updated to include Novartis entity Abadia Retuerta and revised estimate from the Sandoz/Novartis split for manufacturing operations in Austria.
▾ expand
Dependent: Supplier engagement for Scope 3 (95% of emissions) 95% of emissions are Scope 3 generated outside operations. Embedded environmental sustainability into core procurement processes; contracts including environmental sustainability criteria now cover 76% of Scope 3 emissions (up 19 ppts YoY). Onboarded suppliers covering more than two-thirds of Scope 3 emissions. Introduced Environmental Sustainability Supplier Playbook shared with 1000+ suppliers. Participating in WBCSD Partnership for Carbon Transparency.
▾ expand
Primary: PVC elimination and packaging circularity By end of 2024, eliminated 100% of PVC in secondary and tertiary packaging at 24 manufacturing sites handling final product packaging (vs 2016). Established baseline for reducing plastics in packaging and devices. Improved process efficiencies and used more recycled plastics and reusable shipping boxes. Continuing to remove single-use plastics in workplaces.
▾ expand
SBTi-validated near-term and net-zero targets Near-term: reduce Scope 1+2 by 90% and Scope 3 by 42% by 2030 from 2022 base year. Long-term: reduce emissions across all scopes by 90% by 2040 (net zero). 2025 target: carbon neutral in own operations from energy.
▾ expand
see 4 more events →